A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Trial Profile

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs CDX-3379 (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors Celldex Therapeutics
  • Most Recent Events

    • 17 Aug 2017 Status changed from planning to not yet recruiting.
    • 08 Aug 2017 According to a Koltan Pharmaceuticals media release, the company expects to initiate this study in the fourth quarter of 2017.
    • 18 May 2016 According to a Koltan Pharmaceuticals media release, this trial is expected to start in the year 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top